Bispecific Approach Targeting CD19 and CD22 Shows Positive Signs in B-ALL

Article

Investigators trying to find a way to stop antigen loss following CD19 CAR T cell therapy found an approach simultaneously targeting CD19 and CD22 is safe and feasible.

A strategy of simultaneously targeting CD19 and CD22 appears to be feasible and safe in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), according to a new study.

Writing in the Journal of Hematology & Oncology, corresponding author Weidong Han, PhD, of the Institute of Basic Medicine, Chinese People’s Liberation Army General Hospital, in Beijing, and colleagues noted that the first 2 anti-CD19 chimeric antigen receptor-T (CAR-T) therapies approved by the FDA, tisagenlecleucel and axicabtagene, have shown promising results, but with one major caveat.

“Despite the great successes with CAR T cell therapy in leukemia that have been published previously by our group and others, up to 60% of relapses after CD19 CAR T cell therapy are characterized by CD19 antigen loss, which involves several different mechanisms,” Han and colleagues write.

The authors say improvements are needed in the design of CAR T cell therapy to target antigen loss. One potential mechanism is to target multiple antigens on cancer cells. They write that B-ALL is a “compelling” option to test out such a therapy, since anti-CD22 CAR T cell therapies have also demonstrated efficacy against the cancer.

Furthermore, while it’s relatively easy to achieve complete remission in patients with B-ALL, Han and colleagues note less than half of patients achieve a second complete remission upon relapse. They write that preclinical data have suggested a multi-antigen approach has strong potential for these patients, and note that a number of clinical trials are now underway.

In the current study, Han and colleagues enrolled 6 patients with relapsed/refractory precursor B-ALL into a phase I trial of bispecific CAR T cell therapy. The dosing ranged from 1.7 x 106 to 3 x 106 CAR T cells per kilogram of body weight.

The results were promising. The bispecific therapy triggered “robust” cytolytic activity against the target cells, and all 6 patients achieved minimal residual disease-negative (MRD-negative) complete remission. Autologous CD19/CD22 CAR T cells proliferated and were found in the blood, bone marrow, and cerebrospinal fluid of the patients, and none of the 6 patients experienced neurotoxicity, the investigators reported. Unfortunately, the authors also note that after roughly 5 months a single patient had a relapse with blast cells that no longer expressed CD19 and showed diminished CD22 site density.

Han and colleagues write that B-ALL patients who achieve complete remission after CAR T cell therapy don’t have many options for treatment. A possible, though controversial, choice is allogeneic hematopoietic stem cell transplantation (allo-HSCT). The therapy in this study might help allo-HSCT feasible in certain patients, Han and colleagues write.

“In our study, similar to CD19 CAR T cell therapy, bispecific CD19/CD22 CAR T cell therapy provided a temporal window for patients otherwise ineligible or eligible under very suboptimal conditions (MRD+) to bridge to potentially life-saving allo-HSCT.

Han and colleagues say the results of the study warrant further exploration, and they plan to expand their phase I study to better understand the implications in a larger group of patients.

“The results in these patients with relapsed/refractory B-ALL suggest that direct bispecific CD19/CD22 CAR T cells may be necessary to pre-empt antigen escape without exacerbating toxicity,” they conclude.

Reference

Dai, H., Wu, Z., Jia, H. et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol 13, 30 (2020). https://doi.org/10.1186/s13045-020-00856-8.

Recent Videos
Michael Severino on In Vivo Gene Editing With RNA Gene Writers
Jacques Galipeau, MD, on Exponential Progress With Cell and Gene Therapy
Manali Kamdar, MD, on Liso-Cel's Ongoing Benefit in the Treatment Lanscape for LBCL
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Manali Kamdar, MD, on Evaluating Liso-Cel in Mantle Cell Lymphoma by Lines of Therapy, Prior BTKi
Manali Kamdar, MD, on Bringing Liso-Cel to Earlier Lines of Treatment
Omid Hamid, MD, on Assessing TIL Combination Therapies, Expanding Past Melanoma
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Related Content
© 2024 MJH Life Sciences

All rights reserved.